Tongjitang Chinese Medicines' first-quarter 2008 net revenues decreased 29% year-on-year to 105.8 million renminbi ($15.1 million), as sales of Xianling Gubao fell 39% to 70.3 million renminbi and other core products declined 29% to 13.5 million remnimbi.
During the period, the Chinese drugmaker says net income totaled 11.9 million, or 0.35 renminbi per American Depositary Share, 0.09 remnimbi per standard share. According to the firm, this per share performance reflects the 29% increase in the weighted average number of shares used in the calculations, resulting from the company's initial public offering in March 2007.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze